Re: Preliminary comments on Medicare Program; CY 2022 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies [CMS-1751-P] and the Radiation Oncology Model [CMS-1753-P] Dear Secretary Becerra, Administrator Brooks-LaSure, and Deputy Administrator Fowler:On behalf of the Board of Directors of the Community Oncology Alliance (“COA”), we are submitting this letter
No. 18-2926 In the United States Court of Appeals for the Eighth Circuit Pharmaceutical Care Management Association, Plaintiff-Appellant, v. Nizar Wehbi, in his official capacity as the State Health Officer of North Dakota; Mark J. Hardy, in his official capacity as the Executive Director of the North Dakota Board of Pharmacy; Tyler G. Lannoye,
Dear Director Fowler: On behalf of the Board of Directors of the Community Oncology Alliance (“COA”), we are submitting this letter as follow-up to the virtual meeting we held with you and leadership/staff from the Center for Medicare & Medicaid Innovation (“Innovation Center”) on May 11, 2021. We appreciate the time and input that
Community Oncology Alliance Position The Community Oncology Alliance (COA) strongly supports the passage of a federal oral parity law. As of 2019, oral parity laws have passed in 43 states and the District of Columbia; four states have active campaigns; and there is no proposed law in three states. However, these laws differ significantly
Community Oncology Alliance Position The Community Oncology Alliance (COA) opposes the use of prior authorization for certain cancer treatments as it delays important treatment, wastes valuable physician and staff time, and inserts bureaucratic review of treatment decisions by those who are often neither oncologists nor physicians. While prior authorization may have a place for
Community Oncology Alliance Position The Community Oncology Alliance (COA) strongly opposes sequestration cuts to reimbursement for all Medicare Part B drugs purchased to treat cancer. By applying the sequestration cut to the cost of the drug and the six percent administrative add-on, CMS has effectively lowered the reimbursement for the drug, placing a significant
Community Oncology Alliance Position The Community Oncology Alliance (COA) recognizes there are profound and widespread disparities in cancer burden and cancer care among various groups and seeks to diminish these disparities whenever possible. It is estimated that 34 percent of cancer deaths among U.S. adults ages 25 to 74 could be prevented if socioeconomic
Re: Step Therapy for Part B Drugs in Medicare Advantage Dear Secretary Becerra, The undersigned organizations, representing millions of Medicare beneficiaries with life-threatening, complex, chronic conditions and the physicians who care for them, are asking the Centers for Medicare and Medicaid Services (CMS) to ensure that beneficiaries enrolled in Medicare Advantage plans continue to have
Re: Direct and Indirect Remuneration Fees (DIR Fees)Dear Chairman Pallone and Ranking Member McMorris Rodgers:We are writing this letter on behalf of the Board of Directors of the Community Oncology Alliance (COA) respectfully requesting that the Energy & Commerce Committee investigate and hold a hearing on so-called “DIR Fees” used by pharmacy benefit managers (PBMs)
Re: Stopping the Application of Medicare Sequestration Dear Majority Leader Schumer, Minority Leader McConnell, Speaker Pelosi, and Minority Leader McCarthy: We are writing this very important letter on behalf of the Board of Directors of the Community Oncology Alliance (COA) respectfully requesting that the Congress extend the temporary suspension of Medicare sequestration, which will
Resources
Initiatives
EVENTS
Get Involved
© Copyright Community Oncology Alliance | All Rights Reserved | Terms & Conditions | Privacy Policy
